REGULATORY

Chuikyo Payer Rep Moots Higher Prices for Biosames to Incentivize Biosimilar Development

October 24, 2019

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

In a rare move, a payer member of a key reimbursement policy panel on October 23 floated the idea of giving higher prices to so-called “biosame” products over biosimilars to incentivize the costly development of follow-on biologics, describing it as…

To read the full story

Chuikyo Mixed on Integration of Kit Premium into Utility Premiums
October 24, 2019

REGULATORY

Japan Sets New Pricing Rules for Conditionally Approved Regenerative Medicines, Starting with Elevidys
January 15, 2026
MHLW Orders Label Revisions for Aspirin, CAR-T Therapies, and Other Drugs
January 14, 2026
Japan to Stick with 7 New Drug Approval Rounds a Year
January 14, 2026
MHLW to Set Up Expert Panel on Using Disease Registries in Drug Development
January 13, 2026
Chuikyo Moves to Allow Special Mixed-Billing for Santen’s Myopia Drug
January 13, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Gist of FY2026 Drug Pricing Reform Outline

The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…

COMMENTARY

Wave of “World Firsts” Looms as 47 New Drug Candidates Line Up for 2026

By Shinya Sato

As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…